Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA24493 dose-escalation study in acute ischemic stroke
NL-OMON32595Phase 2Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Lu AA24493 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2009; status: active, not recruiting.
02
Drugs
carbamoylated erythropoietin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NL-OMON32595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32595.